CommercialPrior AuthMedium impact
Agalsidase Beta (Fabrazyme®)
BCBS Tennessee·TN · Genetics, Pediatrics, Internal Medicine +1 more·Medical Policy
Effective date
Dec 1, 2026
We identified it
Sep 10, 2026
Summary
BlueCross BlueShield of Tennessee is implementing a new medical policy for Agalsidase Beta (Fabrazyme®) effective December 1, 2026, establishing coverage criteria for Fabry disease treatment in patients age 2+. The policy requires prior authorization with specific documentation including enzyme assay/genetic testing, clinical symptom confirmation, and restricts concurrent use with Elfabrio or Galafold. Continuation therapy requires evidence of positive response (GL-3 reduction, renal improvement, or pain reduction).
Action Required
By November 1, 2026: Billing and prior authorization teams must prepare to implement this new policy. (1) Configure billing system to require prior authorization for all Fabrazyme (Agalsidase Beta) claims for BlueCross BlueShield of Tennessee members. (2) Develop authorization checklist requiring: alpha-galactosidase enzyme assay or genetic testing results, baseline clinical documentation of Fabry disease signs/symptoms, confirmation patient is age 2+, and verification that no concurrent Elfabrio or Galafold therapy exists. (3) Establish 12-month reauthorization workflow requiring evidence of therapeutic response (plasma GL-3/lyso-GL-3 reduction, renal function stability, or pain reduction). (4) Alert prescribing providers that Fabrazyme must be prescribed by metabolic disease or lysosomal storage disorder specialists. (5) Update encounter forms and prior auth request templates to flag exclusionary combinations (Elfabrio, Galafold). (6) Train front desk and authorization staff on new requirements. Claims submitted without proper prior authorization will be denied.